Our Pipeline

Enabled by our proprietary drug discovery platform, we have developed a diverse pipeline of wholly-owned drug candidates.⁽¹⁾

Pipeline graphic is not for promotional use.

Research IND-Enabling Phase 1 Phase 1/2 Phase 3 Regulatory

Updated as of February 2024; (1) Exclusive development and commercialization license with Zai Lab in Greater China for QINLOCK; (2) The patient population for the INSIGHT study consists of second-line GIST patients with mutations in KIT exon 11 and 17 and/or 18 and the absence of mutations in KIT exon 9, 13, and/or 14 (also referred to as KIT exon 11 + 17/18 patients); (3) The Company expects to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vimseltinib for the treatment of patients with TGCT in 2Q 2024 and a Marketing Authorisation Application (MAA) to the European Medicines Agency in 3Q 2024.